| Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma AK Stewart, SV Rajkumar, MA Dimopoulos, T Masszi, I Špička, A Oriol, ... New England Journal of Medicine 372 (2), 142-152, 2015 | 1650 | 2015 |
| Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a … M Attal, PG Richardson, SV Rajkumar, J San-Miguel, M Beksac, I Spicka, ... The Lancet 394 (10214), 2096-2107, 2019 | 708* | 2019 |
| Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma H Avet-Loiseau, R Fonseca, D Siegel, MA Dimopoulos, I Špička, T Masszi, ... Blood, the Journal of the American Society of Hematology 128 (9), 1174-1180, 2016 | 153 | 2016 |
| A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS) R Hájek, T Masszi, MT Petrucci, A Palumbo, L Rosiñol, A Nagler, KL Yong, ... Leukemia 31 (1), 107-114, 2017 | 144 | 2017 |
| Extramedullary disease in multiple myeloma–controversies and future directions S Sevcikova, J Minarik, M Stork, T Jelinek, L Pour, R Hajek Blood reviews 36, 32-39, 2019 | 108 | 2019 |
| Differential diagnosis of incidentally detected adrenal masses revealed on routine abdominal CT F Čtvrtlík, M Heřman, V Študent, V Tichá, J Minařík European journal of radiology 69 (2), 243-252, 2009 | 80 | 2009 |
| Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study FH Schjesvold, MA Dimopoulos, S Delimpasi, P Robak, D Coriu, ... The Lancet Haematology 9 (2), e98-e110, 2022 | 56 | 2022 |
| Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma E Terpos, K Ramasamy, N Maouche, J Minarik, I Ntanasis-Stathopoulos, ... Annals of Hematology 99, 1049-1061, 2020 | 47 | 2020 |
| Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral … J Minarik, P Pavlicek, L Pour, T Pika, V Maisnar, I Spicka, J Jarkovsky, ... PloS one 10 (4), e0123866, 2015 | 47 | 2015 |
| Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and … M Dimopoulos, M Wang, V Maisnar, J Minarik, W Bensinger, MV Mateos, ... Journal of hematology & oncology 11, 1-9, 2018 | 46 | 2018 |
| High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma V Maisnar, R Hájek, V Ščudla, E Gregora, T Büchler, M Tichý, P Kotouček, ... Bone marrow transplantation 41 (1), 51-54, 2008 | 40 | 2008 |
| Limited efficacy of daratumumab in multiple myeloma with extramedullary disease T Jelinek, T Sevcikova, D Zihala, T Popkova, V Kapustova, ... Leukemia 36 (1), 288-291, 2022 | 37 | 2022 |
| Diagnostika a léčba mnohočetného myelomu R Hájek, Z Adam, V Ščudla, V Maisnar, J Bačovský, I Špička, M Krejčí, ... Doporučení vypracované Českou myelomovou skupinou. Transf Hematol dnes 18, 6-89, 2012 | 36 | 2012 |
| Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study A Cowan, F Ferrari, SS Freeman, R Redd, H El-Khoury, J Perry, V Patel, ... The Lancet Haematology 10 (3), e203-e212, 2023 | 34 | 2023 |
| Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine … J Minarik, T Pika, J Radocha, A Jungova, J Straub, T Jelinek, L Pour, ... BMC cancer 21, 1-13, 2021 | 30 | 2021 |
| Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients. J Minarik, T Pika, J Bacovsky, K Langova, V Scudla British journal of haematology 159 (1), 2012 | 30 | 2012 |
| Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement J Minarik, V Scudla, T Tichy, T Pika, J Bacovsky, P Lochman, J Zadrazil Leukemia & Lymphoma 53 (2), 330-331, 2012 | 30 | 2012 |
| Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma E Dementyeva, F Kryukov, L Kubiczkova, P Nemec, S Sevcikova, ... Journal of translational medicine 11, 1-9, 2013 | 29 | 2013 |
| Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities E Kriegova, R Fillerova, J Minarik, J Savara, J Manakova, A Petrackova, ... Scientific reports 11 (1), 14671, 2021 | 27 | 2021 |
| CD 38‐negative relapse in multiple myeloma after daratumumab‐based chemotherapy J Minarik, M Novak, P Flodr, J Balcarkova, M Mlynarcikova, P Krhovska, ... European journal of haematology 99 (2), 186-189, 2017 | 25 | 2017 |
